|
Role of Genetic Factors in the Development of Lung Disease Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Role of Genetic Factors in the Development of Lung Disease conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Role of Genetic Factors in the Development of Lung Disease Clinical research trials and Role of Genetic Factors in the Development of Lung Disease healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Role of Genetic Factors in the Development of Lung Disease. Role of Genetic Factors in the Development of Lung Disease Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Role of Genetic Factors in the Development of Lung Disease clinical trial. Test subjects typically receive the most effective healthcare possible for their Role of Genetic Factors in the Development of Lung Disease condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Role of Genetic Factors in the Development of Lung Disease  Role of Genetic Factors in the Development of Lung Disease
Role of Genetic Factors in the Development of Lung Disease
For Condition: Alpha 1 Antitrypsin Deficiency,Cystic Fibrosis,Lung Disease,Obstructive Lung Disease,Sarcoidosis,Asthma
Status: Recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.
Details: This study is designed to evaluate genetic mechanisms of lung disease by surveying polymorphic genes involved in respiratory function and examining gene expression in the lung cells of individuals with pulmonary disease (e.g., alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease, cystic fibrosis, sarcoidosis). Emphasis will be on defining the distribution of allelic variants of nitric oxide synthase, alpha 1-antitrypsin, and the cystic fibrosis transmembrane conductance regulator genes in patients and in age- and sex-matched healthy individuals in a control population.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Inclusion criteria for patients with AAT deficiency include: (1) Diagnosis of AAT with a confirmed phenotype considered in the high risk category; (2) symptoms consistent with pulmonary disease; (3) chest x-ray consistent with pulmonary disease; (4) pulmonary function tests consistent with pulmonary disease; (5) smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have quit smoking three or more years ago; Inclusion criteria for individuals with chronic obstructive pulmonary diseases include: (1) symptoms consistent with pulmonary disease; (2) chest x-ray consistent with pulmonary disease; (3) pulmonary function tests consistent with pulmonary disease; (4) smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have not smoked for three or more years. Inclusion criteria for patients with cystic fibrosis include a defined genetic mutation (i.e., any of the known variants of the CFTR gene, such as delta F508 allele) or a cystic fibrosis phenotype and clinical features consistent with this disease. Children with cystic fibrosis over eight years of age may be included. Patients with established diagnoses of sarcoidosis, mycobacterial infections, TSC, pulmonary fibrosis, asthma and diabetes mellitus will be included in this protocol. Research volunteers in the pulmonary control group are defined as individuals with no pulmonary disease (e.g. rheumatoid arthritis without evidence of pulmonary disease). Research volunteers in the diabetes control group are defined as individuals with no history of diabetes, coronary artery disease, or pulmonary disease. Because radiation exposure is not required, pregnant women are not excluded from the study. EXCLUSION CRITERIA: Exclusion criteria for all participants include: (1) age less than 18 or greater than 80 except for patients with cystic fibrosis; (2) positive serum test for human immunodeficiency virus; (3) positive serum test for hepatitis virus; and (4) inability to obtain reliable pulmonary function testing. Exclusion criteria for participating in the bronchoscopy portion of the study are: (1) presence of any contraindication for fiberoptic bronchoscopy, with lavage and/or bronchial brushing; (2) advanced stage of a pulmonary or a systemic illness such that the risk is judged to be significant even in the absence of a specific contraindication to the procedure; (3) allergy to topical anesthetic (e.g., lidocaine); (4) current or recent respiratory infection (within the last 4 weeks); (5) pregnancy or lactation; (6) age less than 18 or greater than 65.
Total Enrollment: 2050
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 960100; 96-H-0100
Study Start Date: June 6, 1996
Record last reviewed: May 12, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001532
Other Asthma Studies:
1. Role of Genetic Factors in the Development of Lung Disease
Related Studies:
Other Asthma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Role of Genetic Factors in the Development of Lung Disease
|
|
|
|
|
|
|
|
